Dr. Ghia on the Clinical Implications of the CAPTIVATE Trial in CLL

Paolo Ghia, MD, PhD, discusses the clinical implications of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Paolo Ghia, MD, PhD, full professor, Medical Oncology, head, Strategic Research Program on CLL, Università Vita Salute San Raffaele, deputy director, Division of Experimental Oncology, San Raffaele Scientific Institute, discusses the clinical implications of the phase 2 CAPTIVATE trial (NCT02910583) in chronic lymphocytic leukemia (CLL).

Findings from the primary analysis of the fixed-duration cohort of the CAPTIVATE trial, which were presented during the 2021 ASCO Annual Meeting, demonstrated a complete response (CR) rate of 56% with the fixed-duration combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) in patients with CLL/small lymphocytic lymphoma without a 17p deletion. Moreover, a similar CR rate was observed in patients with high-risk features.

Novel, oral medications given continuously revolutionized the treatment of patients with CLL and extended median progression-free and overall survival, Ghia says. However, fixed-duration treatment could spare patients the long-term adverse effects associated with continuous medication, Ghia says. Also, these regimens could prevent gene mutation recurrences, which lead to drug resistance, concludes Ghia.

Related Videos
Amandeep Godara, MBBS
Eunice Wang, MD
Yvonne Chao, MD, PhD
Ruth M. O’Regan, MD, professor, chair, Charles Ayrault Dewey Professorship of Medicine, Department of Medicine, the University of Rochester, physician-in-chief, Strong Memorial Hospital, associate director, Education and Mentoring, the Wilmot Cancer Institute at University of Rochester,
Timothy Burns, MD, PhD, associate professor of medicine, associate program director, Research, associate program director, Hematology/Oncology Fellowship Program, Department of Medicine, Division of Hematology-Oncology, UPMC Hillman Cancer Center
Sapna Patel, BA, MD
Brian Henick, MD
R. Lor Randall, MD, FACS
Edward B. Garon, MD, MS, professor of medicine, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, the University of California, Los Angeles (UCLA), UCLA Health
Matthew Brunner, MD, assistant professor, hematologic specialist, medical oncology, and palliative care, Department of Medicine, University of Wisconsin Carbone Cancer Center
Related Content